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Objective:
 
 To provide resource utilization patterns and
cost estimates of outpatient care for types I and II diabetes
mellitus in Italy, based on retrospectively collected data.
 
Design:
 
 Multicenter, retrospective observational study
analyzing individual costs in a sample of patients with
diabetes mellitus.
 
Study population:
 
 A total of 2260 patients were strati-
fied into eight groups by type of diabetes, glycemic con-
trol, and age.
 
Setting:
 
 Thirty-five centers for diabetes care in Italy.
 
Results:
 
 The per-patient cost of treatment was 
 
€
 
136.8 in
 
two months for type I diabetes (
 
N
 
 
 

 
 592) and 
 
€
 
123.3 for
type II diabetes (
 
N
 
 
 

 
 1668). Pharmaceutical therapy con-
sisting of antidiabetic drugs only accounted for only 32%
to 36% of treatments cost in type I patients and between
13% and 24% in type II. Diagnostic tests accounted for
27% to 42% of treatment costs in patients with both type
I and type II diabetes, day-hospital days accounted for
15% to 22% in type I, 25% to 27% in type II, and con-
sultations accounted for 16% to 20% in type I patients
and between 17% and 21% in type II diabetes.
 
Conclusion:
 
 Despite limitations caused by the short pe-
riod considered, and considering that in Italy the cost of
diabetes has received limited attention, we believe this
study presents some interesting information on the bur-
den of diabetes in this country.
 
Keywords:
 
 diabetes, resource utilization, Italy, direct
costs, health care.
 
Introduction
 
Diabetes mellitus is one of the most common
chronic pathologies challenging doctors today. It
is among the major causes of death in most devel-
oped countries [1]. The main associated complica-
tions—cardiovascular disease, nephropathy, retin-
opathy, and neuropathy—lead to disability, reduced
life expectancy, and huge health care costs [2].
The economic burden of diabetes and its compli-
cations are considerable in health care and loss of
productivity. Increasing awareness of the economic
burden has led to many studies that address eco-
nomic questions [3–13].
Etiological, clinical, and epidemiological differ-
ences distinguish types I and II diabetes. In turn,
the characteristics of both types of diabetes often
differ from those associated with impaired glucose
tolerance. As a result, the socioeconomic impact
of diabetes is likely to differ in patients with types I
and II diabetes and impaired glucose tolerance [14].
This article provides resource utilization pat-
terns and cost estimates of outpatient care for
types I and II diabetes mellitus in Italy, based on
the retrospectively collected data of the RECORD
(Rilevazione Economica dei COsti e Risorse nel
Diabete) project, a vast study including diabetes
centers that are examining the economic burden
of diabetes in Italy. RECORD was conducted by
CESAV, the Mario Negri Institute Centre for Health
Economics, under the auspices of three Italian
medical societies specializing in diabetes (AMD:
Associazione Medici Diabetologici; SID: Società
Italiana Diabetologia; SIEDP: Società Italiana di
Endocrinologia e Diabetologia Pediatrica). This
article is focused on the cost of treating diabetic
patients in diabetes centers, a selected subgroup of
the entire diabetic patient population. According to
significant estimates [15], in Italy 50% of diabetics
are followed in diabetes centers. These patients are
similar in terms of type of diabetes, age, and ther-
apy to those cared for in general practice. However,
the health care provided in diabetes centers may
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be rather different than in general practice. In fact,
although it is reasonable to assume the absence of
relevant differences in traditional aspects of clini-
cal practice such as cardiovascular risk factor con-
trol and dietetic counseling, a greater diffusion of
the procedures more strictly related to diabetes is
likely in diabetes centers.
 
Methods
 
The RECORD project is a multicenter, observa-
tional study in which 35 diabetes centers located
in 12 different regions of Italy participated: 16
from the north, 10 from the center, and 9 from the
south. Diabetes centers participated in the project
on a voluntary basis. Patients eligible for the study
had a confirmed diagnosis of type I or II diabetes,
had been attending the center for at least two
years, and had been observed there for a follow-
up consultation during a two-month enrollment
period (between May and September 1998). Preg-
nant women were excluded.
Each diabetes center selected between 60 and
100 patients. Eligible patients were enrolled either
consecutively starting from the first day of the en-
rollment period, or randomly according to a com-
puter-generated list. Most centers (28 out of 35)
followed the first method. Information regarding
rate of participation was not collected centrally,
but an informal inquiry estimated eligible patients
who refused to enter the study at a negligible 2.1%.
A total of 2260 patients entered the study. For
the purpose of analysis they were classified into
eight prognostic groups by type of diabetes (type I
or type II), age (age 
 

 
60 or 
 

 
60), and metabolic
control (HbA1c 
 
 
 
or 
 

 
7.5%), as follows:
Group 1: Type I, age 
 

 
60, HbA1c 
 
 
 
7.5%;
Group 2: Type I, age 
 

 
60, HbA1c 
 
 
 
7.5%;
Group 3: Type I, age 
 

 
60, HbA1c 
 
 
 
7.5%;
Group 4: Type I, age 
 

 
60, HbA1c 
 
 
 
7.5%;
Group 5: Type II, age 
 

 
60, HbA1c 
 
 
 
7.5%;
Group 6: Type II, age 
 

 
60, HbA1c 
 
 
 
7.5%;
Group 7: Type II, age 
 

 
60, HbA1c 
 
 
 
7.5%; and
Group 8: Type II, age 
 

 
60, HbA1c 
 
 
 
7.5%.
Metabolic control was evaluated on the basis of
the glycosylated hemoglobin values dating back no
more than 3 months before the interview. Most of
the centers used high-performance liquid chroma-
tography [16] to determine glycosylated hemoglo-
bin, normal values ranging from 3.4% to 6.5%.
Data on resource consumption were collected
retrospectively for the 2 months preceding enroll-
ment using a standardized questionnaire completed
 
by physicians in the participating centers. Personal
information about each patient and data about
complications, day-hospital admissions, drug ther-
apy (oral antidiabetic drugs and insulin only) con-
sultations, laboratory tests, and diagnostic proce-
dures were collected.
 
Cost Estimates
 
The direct costs of diabetes outpatient care were
estimated from the Italian National Health Service
(INHS) perspective. Costs related to hospital ad-
missions and lost production were not included.
The INHS provides universal coverage and com-
prehensive health care free at the point of delivery.
Inpatient and outpatient specialist care is now funded
according to a prospective per-case payment sys-
tem based on region-wide fee schedules, a system
like that of the Diagnosis Related Group (DRG)
introduced in Italy in 1995.
With respect to unit costs, specialist consulta-
tions, diagnostic tests, and day-hospital days were
evaluated according to INHS tariffs. Drug costs
were calculated by multiplying the daily dose by the
consumer price [17]
 
.
 
Data Analysis
 
The mean number of day-hospital days, outpatient
consultations, diagnostic tests, and hours of phar-
maceutical therapy were calculated for each prog-
nostic group. Total costs of diagnosis and treat-
ment were calculated by multiplying each resource
consumed (consultations, diagnostic tests, admis-
sions, and drugs) by its unit cost as identified above.
Per-patient total costs were calculated by dividing
total costs by the total number of patients.
Confidence intervals were calculated for total
costs and subtotals (i.e., day-hospital days, consul-
tations, diagnostic tests, and drugs). Poisson distri-
bution was used for day-hospital and consultation
subtotals since these variables were not normally
distributed. Analysis of variance was used to test
differences between groups (
 
P
 
 
 
 
 
.05).
Covariance analysis was done for total costs to
test the potential effect of the covariates not used
for grouping patients: sex and number of compli-
cations per patient (grouped as 0, 1, 2, 
 

 
3).
 
Results
 
The general characteristics of the study population
are shown in Table 1. The distribution by sex was
fairly balanced in all the prognostic groups. As ex-
pected, the mean age was significantly higher for
patients with type II diabetes. The most frequent
 The Cost of Diabetes in Italy
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complications in patients with type I diabetes were
retinopathy, neuropathy, and arterial hyperten-
sion, and the percentage of affected patients was
significantly higher in the older groups. In patients
with type II diabetes the most frequent complica-
tions were retinopathy, arterial hypertension, and
hyperlipidemia.
Table 2 shows the resources consumed by pa-
tients for diabetes treatment. In general, patients
with type I diabetes had a higher mean number of
consultations than those with type II. Type II pa-
tients had more diagnostic tests and day-hospital
days than type I patients, but these differences
were not statistically significant.
Table 3 shows the cost estimates, i.e., resources
consumed multiplied by their unit costs. These es-
timates are also presented separately by type of di-
abetes (Type I or II), age, and blood glucose con-
trol. The per-patient cost of treatment was 
 
€
 
136.8
in the two months for type I diabetes (
 
N
 
 
 

 
 592)
and 
 
€
 
123.3 for type II diabetes (
 
N
 
 
 

 
 1668). There
were differences between the eight prognostic
groups, but the treatment cost was higher only for
group 4 (
 
€
 
148.8), i.e., patients with type I diabetes
aged over 60 years and with HbA1c 
 

 
 7.5%.
However, this difference was also not statistically
significant.
 
Covariance analysis was also used to take into
account the effect of sex and number of complica-
tions on total costs. The adjusted means of total
costs per patient were, respectively, 
 
€
 
160.2 (STD
13.6), 
 
€
 
157.5 (STD 13.6), 
 
€
 
107.0 (STD 30.0),
 
€
 
126.5 (STD 26.9), 
 
€
 
131.5 (STD 11.4), 
 
€
 
126.9
(STD 12.6), 
 
€
 
115.8 (STD 8.9), 
 
€
 
121.1 (STD 9.4).
Differences between groups were again not signifi-
cant.
Pharmaceutical therapy accounted for 32% to
36% of the treatment cost in type I patients and
13% to 24% in type II. In type I diabetes the high-
est drug cost was for insulin (96–99%) while for
type II it represented only 36% to 57%. Diagnos-
tic tests accounted for 27% to 42% of the treat-
ment cost in types I and II diabetes, day-hospital
days for 15% to 22% in type I patients, 25% to
27% for type II, consultations for 16% to 20% in
type I and 17% to 21% in type II diabetes.
 
Discussion
 
Potential limits of the study must be borne in mind.
First of all, only patients, not centers, were ran-
domly selected and the study population consisted
of patients referred to a network of specialized
centers. They cannot be considered representative
 
Table 2
 
Management of diabetes in an ambulatory setting (mean number per two months per 100 patients)
 
Type I diabetes Type II diabetes
Age
 

 
60 years
 

 
60 years
 

 
60 years
 

 
60 years
HbA1c
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
Number of patients 246 236 49 61 337 273 557 501
Consultations 173.3 194.8 196.2 224.6 189.0 184.8 150.4 177.4
Diabetologic consultations 72.8 86.0 75.6 93.4 70.0 77.4 53.0 68.6
Other specialist consultations 27.6 22.8 45.0 37.8 49.0 30.0 44.4 40.2
Diagnostic tests 581.6 560.2 581.4 637.6 611.8 594.8 585.9 640.4
Glycemia 186.6 200.4 171.4 241.0 186.4 214.2 177.4 211.6
Hba1c 130.0 102.6 104.0 109.8 101.2 94.8 88.6 110.8
Fructosamine 15.0 15.2 18.4 9.8 12.4 11.4 11.6 10.0
Lipidemic profile 21.2 24.6 47.0 32.8 38.2 38.6 35.6 36.2
Microalbuminuria 48.8 43.2 42.8 39.4 38.0 37.6 36.2 42.8
Urine test 53.2 48.8 53.0 57.4 62.8 55.8 51.6 58.8
Urine culture 10.6 5.6 10.2 8.2 16.6 8.4 16.0 12.8
Serum creatinine 28.0 30.0 47.0 46.0 36.8 38.0 36.8 40.6
ECG 14.2 17.0 24.4 24.6 24.6 21.6 32.0 27.0
Autosomic test 7.8 4.2 2.0 1.6 7.4 5.2 9.8 9.0
EMG 2.8 1.2 2.0 3.2 1.4 3.2 2.8 1.6
Neurologic visit 9.8 8.4 18.4 3.2 13.6 13.2 13.6 13.8
Cultures 1.2 1.2 — 1.6 5.0 2.6 3.2 3.2
Lower limb rx 0.4 2.2 — — 4.4 0.8 4.8 3.6
Arteriography — — — — 0.6 — 0.2 0.4
Lower limb Doppler test 3.6 6.4 — 6.6 19.4 11.6 18.6 15.8
Ulcer medication 4.4 10.2 — 19.6 0.6 0.4 11.1 4.8
Fundus oculi examination 32.6 31.4 36.8 28.0 32.6 33.6 29.0 31.2
Fundus photography 4.4 1.6 — 3.2 5.0 1.2 2.2 3.0
Fluoroangiography 7.0 6.0 4.0 1.6 4.8 2.6 4.8 3.4
Day-hospital days 10.2 13.2 8.2 14.8 14.0 13.6 14.4 14.4
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of the Italian diabetic population. However, Ital-
ian centers for diabetes care treat more than half
of the estimated total of Italian diabetics. A study
conducted in northern Italy showed that the two
groups of diabetic patients, those attending and
those not attending diabetes centers, were similar in
terms of class, age, and type of therapy [15]. Also,
the 35 centers participating in this study were well
distributed across the main regions of the country.
Another limit of the study is that resource use
data was retrospectively collected over only two
months of observation. Although the sample of
patients was large, this short time horizon might
not be enough to extrapolate data on a yearly ba-
sis. This study did not consider the costs of hospi-
talization, which account for 30% to 50% of all
diabetes-related costs [18]. This choice was made
because: 1) the low expected rate of hospital ad-
missions in the short period of retrospective analy-
sis was likely to be subject to marked random fluc-
tuation; and 2) collecting precise information on
hospital admissions from the Italian diabetes cen-
ters was difficult because they lack inpatient wards.
Finally, the study did not include indirect costs;
it estimated only direct medical costs from a payer
perspective. Also, unit costs were based on INHS
tariffs rather than on accurate estimates of real
costs for each hospital.
The major strengths of this study include the pos-
sibility of analyzing resource consumption in a large
body of diabetic patients using the same question-
naire for all centers and subjects. This should en-
hance the reliability of results across various age
groups, individual characteristics and lifestyles, and
severities of diabetes.
Most interesting, the analysis provides data
separately for different clinical conditions. In this
study the cost of diabetes treatment was similar in
 
Table 3
 
Per-patient average cost/two months of observation (euros)
 
Type I diabetes Type II diabetes
Age
 

 
60 years
 

 
60 years
 

 
60 years
 

 
60 years
HbA1c
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
 

 
7.5%
Number of patients 246 236 49 61 337 273 557 501
Total cost (euros) 131.2 140.9 126.3 148.8 119.6 122.2 121.5 130.0
CI (112.4–150.7) (125.5–158.1) (96.4–156.4) (113.8–188.3) (102.3–143.6) (107.9–139.7) (100.3–149.4) (117.4–155.1)
Consultations 20.7 22.5 24.9 27.1 24.6 22.2 20.1 22.5
CI* (20.1–21.3) (21.9–23.1) (23.5–26.3) (25.8–28.4) (24.1–25.1) (21.6–22.7) (19.7–20.5) (22.1–22.9)
Diabetologic consultations 15.0 17.8 15.6 19.3 14.5 16.0 10.9 14.2
Other specialist consultations 5.7 4.7 9.3 7.8 10.1 6.2 9.2 8.3
Outpatient diagnostic tests 42.0 38.6 40.5 40.7 47.8 40.1 50.7 45.6
CI (30.3–54.2) (31.7–47.3) (25.0–56.2) (22.2–63.7) (40.9–61.8) (34.5–49.2) (44.2–61.2) (43.7–60.2)
Glycemia 2.4 2.6 2.2 3.1 2.4 2.8 2.3 2.7
Hba1c 13.8 10.9 11.0 11.6 10.7 10.0 9.4 11.7
Fructosamine 0.5 0.5 0.6 0.3 0.4 0.4 0.4 0.3
Lipidemic profile 0.4 0.5 0.9 0.6 0.7 0.7 0.7 0.7
Microalbuminuria 2.3 2.0 2.0 1.8 1.8 1.7 1.7 2.0
Urine test 1.1 1.0 1.1 1.2 1.3 1.2 1.1 1.2
Urine culture 0.9 0.5 0.8 0.7 1.4 0.7 1.3 1.1
Serum creatinine 0.3 0.4 0.6 0.6 0.5 0.5 0.5 0.5
ECG 6.6 7.9 11.3 11.4 11.4 10.0 14.9 12.5
Autosomic test 3.2 1.7 0.8 0.7 3.1 2.1 4.0 0.0
EMG 0.9 0.4 0.6 1.0 0.4 1.0 0.9 0.5
Neurologic visit 2.0 1.7 3.8 0.7 2.8 2.7 2.8 2.9
Cultures 0.2 0.2 — 0.3 0.8 0.4 0.5 0.5
Lower limb rx 0.1 0.4 — — 0.8 0.1 0.9 0.6
Arteriography — — — — 1.7 — 0.6 1.1
Lower limb Doppler test 0.7 1.0 — 0.4 2.6 1.8 2.5 2.2
Ulcer medication 0.7 1.7 — 3.3 0.1 0.1 1.9 0.8
Fundus oculi examination 2.5 2.4 2.9 2.2 2.5 2.6 2.2 2.4
Fundus photography 0.2 0.1 — 0.1 0.2 0.0 0.1 0.1
Fluoroangiography 3.3 2.8 1.9 0.7 2.2 1.2 2.2 1.6
Drugs 45.6 50.3 42.5 47.9 15.9 29.4 18.3 29.6
CI (43.1–48.4) (48.0–52.8) (36.7–48.7) (43.4–52.5) (14.1–17.7) (26.7–32.3) (16.7–19.9) (27.8–31.6)
Biguanides 0.2 — 0.3 0.1 1.4 1.9 0.7 0.5
Sulfonamides 0.0 0.1 — — 3.8 3.6 3.8 3.3
Biguanides & sulfonamides — 0.2 — 0.9 3.6 7.5 3.9 6.4
Acarbosium 0.5 0.4 0.7 0.9 1.4 2.9 1.6 2.4
Insulin 44.9 49.6 41.5 46.0 5.7 13.5 8.3 17.0
Insulin/total 98% 99% 98% 96% 36% 46% 46% 57%
Day-hospital days 22.9 29.6 18.4 33.2 31.4 30.5 32.3 32.3
CI* (22.3–23.5) (28.9–30.3) (17.2–19.6) (31.8–34.6) (30.8–32.0) (29.8–31.2) (31.8–32.8) (31.8–32.8)
*CI calculated using Poisson distribution.
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patients with type II diabetes independent of pa-
tient age or metabolic control. The cost tended to
be lower in patients with type I diabetes, except
those over 60 years of age with poor metabolic
control. Unfortunately, it is difficult to compare
these results with published data, which generally
refer to all diabetes patients, or to break them
down to type I or type II only.
Among outpatient costs the proportion of cost
for drugs accounted for 32% to 36% in type I dia-
betics, but 13% to 24% in type II, depending on
age and metabolic control. Considering all pa-
tients, drugs accounted for about 27% of the total
cost. Published figures on this issue are controver-
sial. In some studies, drug costs are the major
component of treatment of diabetes excluding
hospitalization [19–21], but in others, drug costs
were less than 20% [22–24]. Most of these differ-
ences reflect different methods of data collection,
and particularly the types of costs included. Most
of the studies do not indicate what drugs, types of
laboratory tests, and consultations were consid-
ered. For example, comparing the results of this
study with others [18], it should be remembered
that only oral antidiabetic drugs and insulin costs
were considered. Costs of the treatment of compli-
cations were excluded, and only the costs of diag-
nosing complications were included. This method-
ological choice stems from the difficulties, in the
absence of a nondiabetic control group, of attrib-
uting to diabetes the cost of treating cardiovascu-
lar disease or other pathologies for which diabetes
is a risk factor but not the only cause. This prob-
lem is particularly evident in older diabetic pa-
tients who have a high prevalence of comorbidity.
In conclusion, despite the limitations of the
short period analyzed, and considering that in Italy
the cost of diabetes has received limited attention,
we believe this study offers some interesting infor-
mation on the burden of diabetes in this country.
In particular, this information can serve as a base-
line for further economic evaluations of new thera-
pies in diabetes care and may also be useful for
health care decision makers who need to plan health
care services with limited financial resources.
The analysis showed that the cost of diabetes,
excluding complications, is not significantly affected
by the diabetes type, metabolic control, or age.
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